Feature|Articles|October 15, 2026

FAQs: The AUA 2025 Guideline on Genitourinary Syndrome of Menopause

Fact checked by: Benjamin P. Saylor, Strategic Content Lead

These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline.

At the 27th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) in October 2026, Engy Habashy, MD, a urologist at Genesis Medical Center in Columbus, Ohio, delivered a talk titled "No Progesterone Required, Androgens Welcome: Clinical Pearls from the 2025 AUA GSM Guidelines." Her presentation centered on the American Urological Association (AUA) 2025 Guideline on the Genitourinary Syndrome of Menopause (GSM), released in April 2025 in partnership with the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) and the American Urogynecologic Society (AUGS).¹

Related to this article

October 1st, 2026

Pearls & Perspectives: Navigating Supplements in Pelvic and Sexual Health, with Heather Florio

Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.

October 15th, 2026

Three-year data show durable responses with mitomycin intravesical solution

Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.

October 15th, 2026

Armine K. Smith, MD, on sexual health counseling before cystectomy

Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.

October 14th, 2026

FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC

This approval expands the label for nogapendekin alfa inbakicept to include patients with high-grade papillary-only tumors.

October 14th, 2026

Study assesses real-world outcomes with intranasal vardenafil for ED

Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.